Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients

Pharmaceutical Research

Volumn 16, Issue 5, 1999, Pages 718-724

  Carver, Peggy L ^a   Fleisher, David ^a   Zhou, Simon Y ^a   Kaul, Daniel ^b   Kazanjian, Powel ^b   Li, Cheng ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Food effect; Indinavir; Meal effect; Oral absorption; Protease inhibitors

Indexed keywords

INDINAVIR; L 738804; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; FOOD COMPOSITION; FOOD INTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEAL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; TELEMETRY;

ADULT; AGED; CROSS-OVER STUDIES; EATING; GASTRIC ACIDITY DETERMINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; INDINAVIR; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; VISCOSITY;

EID: 0032909820     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018880726035     Document Type: Article

References (16)

1. 1. C. J. Kenyon, E Brown, G. R. McClelland, and I. R. Wilding. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir). Pharm. Res., 15:417-22 (1998).
2. 2. C. M. Perry and P. Benfield. Nelfinavir, ADIS new drug profile, Drugs, 54:81-87, (1997).
3. 3. C. M. Perry and S. Noble. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs, 55:461-86 (1998).
4. 4. K. C. Yeh, P. J. Deutsch, H. Haddix, M. Hesney, V. Hoagland, W. D. Ju, S. J. Justice, B. Osborne, A. T. Sterrett, J. A. Stone, E. Woolf, and S. Waldman. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. 42:332-8 (1998).
5. 5. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-94 (1998).
6. 6. J. H. Lin, I. W. Chen, K. J. Vastag, and D. Ostovic. pH-dependent oral absorption of L-735,524, a potent HIVprotease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:730-5 (1995).
7. 7. L. H. Pao, S. Y. Zhou, C. Cook, T. Kararli, C. Kirchhoff, J. Truelove, A. Karim, and D. Fleisher. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Pharm. Res. 15:221-7 (1998).
8. 8. D. M. Burger, M. de Graaff, E. W. Wuis, P. P. Koopmans, and Y. A. Hekster. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J. Chromat. B. Biomed. Sci. Applic. 703:235-41 (1997).
9. 9. I. W. Chen, K. J. Vastag, and J. H. Lin. High-performance liquid Chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J. Chromat. B. Biomed. Applic. 672:111-7 (1995).
10. 10. B. D. Dorsey, R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, and J. C. Quintero. et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-51 (1994).
11. 11. C. Miles, P. Dickson, K. Rana, C. Lippert, and D. Fleisher. CCK antagonist pre-treatmem inhibits meal-enhanced drug absorption in dogs, Regul. Pep. 68:9-14 (1997)
12. 12. M. P. Grosvenor and J. E. Lofroth, Interaction between bile salts and β-adrenoceptor antagonists, Pharm. Res. 12:682-686 (1995)
13. 13. C. Reppas, J. H. Meyer, P. J. Sirois, and J. B. Dressman. Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. Gastroent. 100:1217-23 (1991)
14. 14. A. Hsu, R. Granneman, M. Heath-Chiozzi, C. Wong, L. Manning, R. Brooks, and E. Sun. Indinavir can be taken with regular meals when adminstistered with ritonavir. Int. Conf. AIDS. 12:336 (1998).
15. 15. T. Koudriakova, E. Iatsimirskaia, I. Utkin, E. Gangl, P. Vouros, E. Storozhuk, D. Orza, J. Marinina, and N. Gerber. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26:552-61 (1998).
16. 16. S. K. Balani, E. J. Woolf, V. L. Hoagland, M. G. Sturgill, P. J. Deutsch, K. C. Yen, and J. H. Lin. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 24:1389-94 (1996).